BASKING RIDGE, N.J., Nov. 2, 2010 /PRNewswire/ — Regado
Biosciences, Inc., a privately held company leading the development
of antithrombotic aptamers with active control agents, announced
that Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President
and Chief Medical Officer, presented an abstract at the American
College of Chest Physicians (ACCP) Coagulation and Heart Disease
Sessions on November 2, 2010 in Vancouver, BC, Canada. The
abstract is titled “Sustained Inhibition of Factor IXa by
Subcutaneous RB006 with Active Reversal: First-in-Human Experience
with the REG2 System.”
The REG2 system is intended for use in venous thrombosis
indications. This initial Phase 1 study was the first
successful subcutaneous application of an aptamer in humans.
It demonstrated that a single subcutaneous injection of RB006
(aka pegnivacogin) resulted in dose-dependent inhibition of Factor
IXa with effects that persisted longer than one week after
injection. The data is promising for future development of
REG2.
The abstract is coauthored by Steven L. Zelenkofske, D.O.,
Christopher P. Rusconi, Ph.D. and Carolyn M. Darmiento, MS, all
from Regado Biosciences; and Richard C. Becker, MD, Duke University
School of Medicine, Durham, NC and William Wargin, Ph.D., President
of PK-PM Associates, LLC.
ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private
biopharmaceutical company pioneering a new therapeutic technology
with the creation and development of proprietary controllable
aptamer drug systems. Each system comprises a
nuclease-stabilized RNA aptamer, the therapeutic effect of which
can be reversed partially or completely in real time by its
specific and complementary oligonucleotide active control agent.
This technology is being applied to injectable antithrombotics
(including anticoagulants and antiplatelet agents) in the acute and
sub-acute care cardiovascular setting, a multi-billion dollar
world-wide market i
‘/>”/>
